Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Diabetes

Free Subscription Articles published in Ann Intern Med Retrieve available abstracts of 138 articles: HTML format

Single Articles

January 2025
1. 
   Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
   Ann Intern Med. 2025 Jan 7:e2403525VS. doi: 10.7326/ANNALS-24-03525.
   PubMed    
   
   
   
2. 
   Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
   Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
   PubMed    
   
   
   
3. MOIZ A, Filion KB, Toutounchi H, Tsoukas MA, et al
   Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
   Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
   PubMed     Abstract available
   
   
   December 2024
4. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed     Abstract available
   
   
   
5. GIANCHANDANI R, Wei M, Demidowich A
   Management of Hyperglycemia in Hospitalized Patients.
   Ann Intern Med. 2024;177:ITC177-ITC192.
   PubMed     Abstract available
   
   
   November 2024
6. ZHU D, Herrington WG
   In adults with BMI >/=27 kg/m(2) and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA(1c) level.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02457.
   PubMed     Abstract available
   
   
   
7. MAHER M, Dinneen S
   In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
   Ann Intern Med. 2024;177:JC124.
   PubMed     Abstract available
   
   
   
8. ZHU D, Herrington WG
   In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
   Ann Intern Med. 2024;177:JC123.
   PubMed     Abstract available
   
   
   October 2024
9. FITCH KV, Zanni MV, Manne-Goehler J, Diggs MR, et al
   Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.
   Ann Intern Med. 2024 Oct 8. doi: 10.7326/ANNALS-24-00944.
   PubMed     Abstract available
   
   
   
10. HONG B, Bea S, Ko HY, Kim WJ, et al
    Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.
    Ann Intern Med. 2024;177:1319-1329.
    PubMed     Abstract available
    
    
    September 2024
11. COLLISTER D, Pannu N
    In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
    Ann Intern Med. 2024;177:JC98.
    PubMed     Abstract available
    
    
    
12. YEO YH, Rezaie A, Hsieh TY, Hu X, et al
    Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.
    Ann Intern Med. 2024;177:1289-1291.
    PubMed    
    
    
    August 2024
13. CHAITOFF A, Bendicksen L, Feldman WB, Zheutlin AR, et al
    Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
    Ann Intern Med. 2024 Aug 27. doi: 10.7326/ANNALS-24-00308.
    PubMed    
    
    
    
14. KANJEE Z, Brown FM, Taxin ZH, Smetana GW, et al
    How Would You Treat This Inpatient With Type 2 Diabetes Mellitus? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Aug 13. doi: 10.7326/ANNALS-24-01100.
    PubMed     Abstract available
    
    
    July 2024
15. WANG W, Volkow ND, Berger NA, Davis PB, et al
    Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
    Ann Intern Med. 2024 Jul 30. doi: 10.7326/M23-2718.
    PubMed     Abstract available
    
    
    
16. TANG H, Lu Y, Donahoo WT, Shao H, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/M24-0329.
    PubMed     Abstract available
    
    
    
17. 
    Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/P24-0004.
    PubMed    
    
    
    
18. CENTOR RM, Crandall CJ
    Annals On Call - ACP Recommendation: Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2024;177:e2401521OC.
    PubMed    
    
    
    
19. TANNER M
    In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality.
    Ann Intern Med. 2024;177:JC83.
    PubMed     Abstract available
    
    
    
20. CHIU YH, Huybrechts KF, Patorno E, Yland JJ, et al
    Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data.
    Ann Intern Med. 2024;177:862-870.
    PubMed     Abstract available
    
    
    June 2024
21. CRAWFORD AL, Laiteerapong N
    Type 2 Diabetes.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/AITC202406180.
    PubMed     Abstract available
    
    
    
22. SMETANA GW, Romeo GR, Rosas SE, Burns RB, et al
    How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/M24-0764.
    PubMed     Abstract available
    
    
    May 2024
23. LAINE C, Moyer DV, Qaseem A
    Newer Pharmacologic Treatments for Type 2 Diabetes.
    Ann Intern Med. 2024 May 28. doi: 10.7326/ANNALS-24-00698.
    PubMed    
    
    
    
24. O'BRIEN C, Dinneen SF
    In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0028.
    PubMed     Abstract available
    
    
    
25. BATES ER
    In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026.
    PubMed     Abstract available
    
    
    
26. MARUTHUR NM, Pilla SJ, White K, Wu B, et al
    Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial.
    Ann Intern Med. 2024;177:549-558.
    PubMed     Abstract available
    
    
    April 2024
27. YEN FS, Hwu CM, Liu JS, Wu YL, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Ann Intern Med. 2024 Apr 30. doi: 10.7326/M23-1874.
    PubMed     Abstract available
    
    
    
28. DRAKE T, Landsteiner A, Langsetmo L, MacDonald R, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1490.
    PubMed     Abstract available
    
    
    
29. SCHOUSBOE JT, Landsteiner A, Drake T, Sultan S, et al
    Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1492.
    PubMed     Abstract available
    
    
    
30. QASEEM A, Obley AJ, Shamliyan T, Hicks LA, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-2788.
    PubMed     Abstract available
    
    
    
31. SYED FZ
    Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M24-0861.
    PubMed    
    
    
    
32. 
    Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Apr 19:eM231554. doi: 10.7326/M23-1554.
    PubMed    
    
    
    
33. 
    Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19:eM240803. doi: 10.7326/M24-0803.
    PubMed     Abstract available
    
    
    
34. KELSEY M, Newby LK
    In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
    Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0016.
    PubMed     Abstract available
    
    
    
35. HWANG JH, Hsu CY
    In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
    Ann Intern Med. 2024;177:JC40.
    PubMed     Abstract available
    
    
    
36. EGAN AM
    In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.
    Ann Intern Med. 2024;177:JC47.
    PubMed     Abstract available
    
    
    March 2024
37. GARABEDIAN LF, Zhang F, Costa R, Argetsinger S, et al
    Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
    Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-1965.
    PubMed     Abstract available
    
    
    
38. KOUTROUMPAKIS E, Deswal A
    In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
    Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0008.
    PubMed     Abstract available
    
    
    
39. PERSELL SD, Petito LC, Lee JY, Meeker D, et al
    Reducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial.
    Ann Intern Med. 2024;177:324-334.
    PubMed     Abstract available
    
    
    February 2024
40. PAPPACHAN JM
    In T2DM with obesity, time-restricted eating increased weight loss and reduced HbA(1c) level at 6 mo.
    Ann Intern Med. 2024;177:JC16.
    PubMed     Abstract available
    
    
    January 2024
41. CASEY C, Dinneen SF
    In latent autoimmune diabetes in adults, mortality was similar to T2DM but retinopathy was higher at 5.9 y.
    Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0107.
    PubMed     Abstract available
    
    
    
42. WEITZ HH, Merli GJ
    Annals Consult Guys - Postoperative Euglycemic Diabetic Ketoacidosis.
    Ann Intern Med. 2024;177:eW230012.
    PubMed    
    
    
    
43. LIAKOS A, Karagiannis T, Tsapas A
    In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA(1c) vs. daily basal insulin analogues at 52 wk.
    Ann Intern Med. 2024;177:JC6.
    PubMed     Abstract available
    
    
    December 2023
44. CENTOR RM, Fang M
    Annals On Call - Type 1 Diabetes: Age at Diagnosis.
    Ann Intern Med. 2023 Dec 5:eA220023. doi: 10.7326/A22-0023.
    PubMed    
    
    
    
45. AGARWAL R, Tu W, Farjat AE, Farag YMK, et al
    Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
    Ann Intern Med. 2023 Dec 5. doi: 10.7326/M23-1023.
    PubMed     Abstract available
    
    
    November 2023
46. LIU M, Aggarwal R, Zheng Z, Yeh RW, et al
    Cardiovascular Health of Middle-Aged U.S. Adults by Income Level, 1999 to March 2020 : A Serial Cross-Sectional Study.
    Ann Intern Med. 2023 Nov 21. doi: 10.7326/M23-2109.
    PubMed     Abstract available
    
    
    
47. 
    Correction: Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes.
    Ann Intern Med. 2023 Nov 7. doi: 10.7326/L23-0410.
    PubMed    
    
    
    
48. DAVIDSON MB
    In adults with BMI >/=27 kg/m(2) and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
    Ann Intern Med. 2023 Nov 7. doi: 10.7326/J23-0089.
    PubMed     Abstract available
    
    
    
49. NABRDALIK K, Lip GYH
    In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes.
    Ann Intern Med. 2023 Nov 7. doi: 10.7326/J23-0081.
    PubMed     Abstract available
    
    
    October 2023
50. LAU D
    In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
    Ann Intern Med. 2023 Oct 3. doi: 10.7326/J23-0077.
    PubMed     Abstract available
    
    
    
51. BELAL H, Gandhi GY
    In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA(1c) vs. daily glargine at 52 wk.
    Ann Intern Med. 2023;176:JC113.
    PubMed     Abstract available
    
    
    
52. BELAL H, Gandhi GY
    In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA(1c) vs. daily degludec at 26 wk.
    Ann Intern Med. 2023;176:JC112.
    PubMed     Abstract available
    
    
    September 2023
53. FANG M, Wang D, Echouffo-Tcheugui JB, Selvin E, et al
    Age at Diagnosis in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023 Sep 26. doi: 10.7326/M23-1707.
    PubMed    
    
    
    
54. BAJAJ HS, Aberle J, Davies M, Donatsky AM, et al
    Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
    Ann Intern Med. 2023 Sep 26. doi: 10.7326/M23-1288.
    PubMed     Abstract available
    
    
    
55. KIANERSI S, Liu Y, Guasch-Ferre M, Redline S, et al
    Chronotype, Unhealthy Lifestyle, and Diabetes Risk in Middle-Aged U.S. Women : A Prospective Cohort Study.
    Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-0728.
    PubMed     Abstract available
    
    
    
56. LIN K, Song M, Giovannucci E
    Evening Chronotype, Circadian Misalignment, and Metabolic Health: Implications for Diabetes Prevention and Beyond.
    Ann Intern Med. 2023 Sep 12. doi: 10.7326/M23-2257.
    PubMed    
    
    
    
57. FANG M, Echouffo-Tcheugui JB, Selvin E
    Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023;176:eL230228.
    PubMed    
    
    
    
58. POPOVIC D, Patoulias D, Papanas N
    Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023;176:eL230227.
    PubMed    
    
    
    August 2023
59. ZHONG VW, Yu D, Zhao L, Yang Y, et al
    Achievement of Guideline-Recommended Targets in Diabetes Care in China : A Nationwide Cross-Sectional Study.
    Ann Intern Med. 2023 Aug 1. doi: 10.7326/M23-0442.
    PubMed     Abstract available
    
    
    
60. HANDS JM, Patrick R, Frame LA
    Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023;176:eL230201.
    PubMed    
    
    
    
61. PITTAS AG, Kawahara T, Jorde R, Dawson-Hughes B, et al
    Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023;176:eL230202.
    PubMed    
    
    
    
62. BELAL H, Gandhi GY
    In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA(1c) at 26 wk.
    Ann Intern Med. 2023;176:JC94.
    PubMed     Abstract available
    
    
    July 2023
63. MCCORMICK N, Yokose C, Wei J, Lu N, et al
    Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
    Ann Intern Med. 2023 Jul 25. doi: 10.7326/M23-0724.
    PubMed     Abstract available
    
    
    
64. 
    Correction: Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Ann Intern Med. 2023 Jul 18. doi: 10.7326/L23-0249.
    PubMed    
    
    
    
65. LOCKHART MJ, Dinneen SF
    In type 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA(1c) at 26 wk.
    Ann Intern Med. 2023 Jul 4. doi: 10.7326/J23-0046.
    PubMed     Abstract available
    
    
    
66. LOCKHART MJ, Dinneen SF
    In type 1 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA(1c) at 26 wk.
    Ann Intern Med. 2023 Jul 4. doi: 10.7326/J23-0045.
    PubMed     Abstract available
    
    
    
67. PATOULIAS D
    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
    Ann Intern Med. 2023;176:eL230069.
    PubMed    
    
    
    
68. SCHECHTER M, Chertow GM, Heerspink HJL
    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
    Ann Intern Med. 2023;176:eL230070.
    PubMed    
    
    
    June 2023
69. SLOAN CE, Campagna A, Tu K, Doerstling S, et al
    Online Crowdfunding Campaigns for Diabetes-Related Expenses.
    Ann Intern Med. 2023 Jun 13. doi: 10.7326/M23-0540.
    PubMed    
    
    
    May 2023
70. NISSEN SE
    Comparative Effectiveness of Diabetes Drugs: The Use and Misuse of Observational Research.
    Ann Intern Med. 2023 May 9. doi: 10.7326/M23-0958.
    PubMed    
    
    
    
71. RICHARDSON TL JR, Halvorson AE, Hackstadt AJ, Hung AM, et al
    Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Ann Intern Med. 2023 May 9. doi: 10.7326/M22-2751.
    PubMed     Abstract available
    
    
    
72. VAN NORMAN M, Molony DA
    KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD.
    Ann Intern Med. 2023 May 2. doi: 10.7326/J23-0023.
    PubMed     Abstract available
    
    
    
73. LAU D
    In prediabetes, oral vitamin D reduces progression to new-onset diabetes.
    Ann Intern Med. 2023 May 2. doi: 10.7326/J23-0030.
    PubMed     Abstract available
    
    
    April 2023
74. HANNA C, Pettersen K, Pedley N
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Ann Intern Med. 2023;176:eL230006.
    PubMed    
    
    
    
75. ADIE SK, Konerman MC
    Annals for Hospitalists Inpatient Notes - Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction-What Hospitalists Need to Know.
    Ann Intern Med. 2023;176:eM230588.
    PubMed    
    
    
    
76. LAITEERAPONG N, Alexander J, Philipson L, Winn AN, et al
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Ann Intern Med. 2023;176:eL230007.
    PubMed    
    
    
    
77. CARRIAZO S, Ortiz A, Fernandez-Fernandez B
    First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Ann Intern Med. 2023;176:eL230005.
    PubMed    
    
    
    
78. TANG S, Shao H, Ali MK, Zhang P, et al
    Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample.
    Ann Intern Med. 2023;176:582-583.
    PubMed    
    
    
    March 2023
79. PATEL T
    SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes.
    Ann Intern Med. 2023 Mar 7. doi: 10.7326/J23-0002.
    PubMed     Abstract available
    
    
    
80. KWONG YD, Hsu CY
    In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y.
    Ann Intern Med. 2023;176:JC26.
    PubMed     Abstract available
    
    
    February 2023
81. FANG M, Jeon Y, Echouffo-Tcheugui JB, Selvin E, et al
    Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
    Ann Intern Med. 2023 Feb 14. doi: 10.7326/M22-3078.
    PubMed    
    
    
    
82. 
    Summary for Patients: Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023 Feb 7. doi: 10.7326/P22-0031.
    PubMed    
    
    
    
83. MCKENNA MJ, Flynn MAT
    Preventing Type 2 Diabetes With Vitamin D: Therapy Versus Supplementation.
    Ann Intern Med. 2023 Feb 7. doi: 10.7326/M23-0220.
    PubMed    
    
    
    
84. PITTAS AG, Kawahara T, Jorde R, Dawson-Hughes B, et al
    Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials.
    Ann Intern Med. 2023 Feb 7. doi: 10.7326/M22-3018.
    PubMed     Abstract available
    
    
    
85. 
    Annals Video Summary - Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes.
    Ann Intern Med. 2023 Feb 7:eM223698. doi: 10.7326/M22-3698.
    PubMed    
    
    
    
86. CENTOR RM, Laiteerapong N, Winn AN
    Annals On Call - First-Line Drug Therapy for Type 2 Diabetes.
    Ann Intern Med. 2023;176:eA220004.
    PubMed    
    
    
    January 2023
87. 
    Correction: 2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease.
    Ann Intern Med. 2023 Jan 17. doi: 10.7326/L23-0010.
    PubMed    
    
    
    
88. NAVANEETHAN SD, Zoungas S, Caramori ML, Chan JCN, et al
    Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.
    Ann Intern Med. 2023 Jan 10. doi: 10.7326/M22-2904.
    PubMed     Abstract available
    
    
    
89. SAUNDERS M, Laiteerapong N
    2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to Do.
    Ann Intern Med. 2023 Jan 10. doi: 10.7326/M22-3635.
    PubMed    
    
    
    
90. BROWN K, Donato AA
    In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
    Ann Intern Med. 2023 Jan 3. doi: 10.7326/J22-0105.
    PubMed     Abstract available
    
    
    
91. BROWN K, Donato AA
    In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Ann Intern Med. 2023 Jan 3. doi: 10.7326/J22-0104.
    PubMed     Abstract available
    
    
    
92. GREENBLATT LH
    In type 2 diabetes, the BT-001 smartphone app reduced HbA(1c) more than a control app at 90 d.
    Ann Intern Med. 2023 Jan 3. doi: 10.7326/J22-0109.
    PubMed     Abstract available
    
    
    
93. LOCKHART M, Dinneen SF
    In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumps.
    Ann Intern Med. 2023;176:JC11.
    PubMed     Abstract available
    
    
    December 2022
94. 
    Summary for Patients: Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/P22-0022.
    PubMed    
    
    
    
95. HANSEN CD, Gram-Kampmann EM, Hansen JK, Hugger MB, et al
    Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-1787.
    PubMed     Abstract available
    
    
    
96. CARR JC
    BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/J22-0093.
    PubMed     Abstract available
    
    
    
97. SHI X, He J, Lin M, Liu C, et al
    Comparative Effectiveness of Team-Based Care With and Without Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/M22-1950.
    PubMed     Abstract available
    
    
    
98. 
    Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/P22-0020.
    PubMed    
    
    
    
99. SCHECHTER M, Jongs N, Chertow GM, Mosenzon O, et al
    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
    Ann Intern Med. 2022 Dec 6. doi: 10.7326/M22-2115.
    PubMed     Abstract available
    
    
    
100. SHIN H, Schneeweiss S, Glynn RJ, Patorno E, et al
     Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.
     Ann Intern Med. 2022;175:W155.
     PubMed    
     
     
     
101. QIU M
     Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.
     Ann Intern Med. 2022;175:W155.
     PubMed    
     
     
     October 2022
102. FUDIM M, Van Spall HGC
     In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.
     Ann Intern Med. 2022 Oct 4. doi: 10.7326/J22-0075.
     PubMed     Abstract available
     
     
     
103. CHOI JG, Winn AN, Skandari MR, Franco MI, et al
     First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
     Ann Intern Med. 2022 Oct 4. doi: 10.7326/M21-2941.
     PubMed     Abstract available
     
     
     
104. DAVIDSON MB
     In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
     Ann Intern Med. 2022 Oct 4. doi: 10.7326/J22-0072.
     PubMed     Abstract available
     
     
     September 2022
105. RACHMASARI K, Montori VM
     In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia.
     Ann Intern Med. 2022 Sep 6. doi: 10.7326/J22-0063.
     PubMed     Abstract available
     
     
     August 2022
106. MONTORI VM
     Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19.
     Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0052.
     PubMed     Abstract available
     
     
     
107. TANNER M
     In diabetes, some statins reduce non-HDL-C better than others vs. placebo.
     Ann Intern Med. 2022 Aug 2. doi: 10.7326/J22-0051.
     PubMed     Abstract available
     
     
     
108. BROPHY JM
     In HF, SGLT2 inhibitors reduce HF hospitalizations at up to 2 y.
     Ann Intern Med. 2022;175:JC87.
     PubMed     Abstract available
     
     
     June 2022
109. BUTT JH, Dewan P, Merkely B, Belohlavek J, et al
     Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
     Ann Intern Med. 2022;175:820-830.
     PubMed     Abstract available
     
     
     
110. ZOU X, Shi Q, Vandvik PO, Guyatt G, et al
     Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis.
     Ann Intern Med. 2022;175:851-861.
     PubMed     Abstract available
     
     
     May 2022
111. SHIN H, Schneeweiss S, Glynn RJ, Patorno E, et al
     Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
     Ann Intern Med. 2022 May 24. doi: 10.7326/M21-4012.
     PubMed     Abstract available
     
     
     
112. NGO-METZGER Q
     Diabetes Screening: Different Thresholds for Different Racial/Ethnic Groups.
     Ann Intern Med. 2022 May 10. doi: 10.7326/M22-1235.
     PubMed    
     
     
     
113. AGGARWAL R, Bibbins-Domingo K, Yeh RW, Song Y, et al
     Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds.
     Ann Intern Med. 2022 May 10. doi: 10.7326/M20-8079.
     PubMed     Abstract available
     
     
     
114. 
     Summary for Patients: Screening for Diabetes by Race and Ethnicity in the United States.
     Ann Intern Med. 2022 May 10. doi: 10.7326/P22-0008.
     PubMed    
     
     
     
115. KAUFFMAN RP
     In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
     Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0023.
     PubMed     Abstract available
     
     
     
116. MAYNE KJ, Herrington WG
     In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes.
     Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0029.
     PubMed     Abstract available
     
     
     
117. CENTOR RM, Syed FZ
     Annals On Call - Type 1 Diabetes Mellitus in Adults.
     Ann Intern Med. 2022 May 3:OC1. doi: 10.7326/A21-0010.
     PubMed    
     
     
     
118. WENSINK MJ, Lu Y, Tian L, Shaw GM, et al
     Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study.
     Ann Intern Med. 2022;175:665-673.
     PubMed     Abstract available
     
     
     April 2022
119. TANNER M
     Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class.
     Ann Intern Med. 2022 Apr 5. doi: 10.7326/J22-0018.
     PubMed     Abstract available
     
     
     March 2022
120. LOUIS GMB
     Paternal Preconception Diabetes Drugs and Birth Defects in Offspring: A Call for More Conclusive Study.
     Ann Intern Med. 2022 Mar 29. doi: 10.7326/M22-0770.
     PubMed    
     
     
     
121. SYED FZ
     Type 1 Diabetes Mellitus.
     Ann Intern Med. 2022 Mar 8. doi: 10.7326/AITC202203150.
     PubMed     Abstract available
     
     
     
122. SINGH M
     In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk.
     Ann Intern Med. 2022 Mar 1. doi: 10.7326/J22-0009.
     PubMed     Abstract available
     
     
     
123. KELSEY MD, Newby LK
     In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.
     Ann Intern Med. 2022;175:JC26.
     PubMed     Abstract available
     
     
     
124. PRETE A, Subramanian A, Bancos I, Chortis V, et al
     Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study.
     Ann Intern Med. 2022;175:325-334.
     PubMed     Abstract available
     
     
     February 2022
125. HUANG HK, Liu PP, Lin SM, Hsu JY, et al
     Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants : A Nationwide Analysis.
     Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-3498.
     PubMed     Abstract available
     
     
     
126. 
     The National Clinical Care Commission Report: Improving Federal Programs That Impact Diabetes Prevention and Care.
     Ann Intern Med. 2022 Feb 15. doi: 10.7326/M21-4175.
     PubMed    
     
     
     January 2022
127. PATORNO E, Htoo PT, Everett BM, Kim SC, et al
     Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
     Ann Intern Med. 2022;175:W4.
     PubMed    
     
     
     
128. PATORNO E, Htoo PT, Glynn RJ, Schneeweiss S, et al
     Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
     Ann Intern Med. 2022;175:W4-W5.
     PubMed    
     
     
     
129. BEPO L, Makam AN, Nguyen OK
     Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
     Ann Intern Med. 2022;175:W3.
     PubMed    
     
     
     
130. QIU M
     Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
     Ann Intern Med. 2022;175:W3-W4.
     PubMed    
     
     
     November 2021
131. 
     Summary for Patients: Do Gastric Bypass and Sleeve Gastrectomy Help Reduce Liver Fat Content and Scarring in Patients With Type 2 Diabetes?
     Ann Intern Med. 2021 Nov 30. doi: 10.7326/P21-0012.
     PubMed    
     
     
     
132. SEEBERG KA, Borgeraas H, Hofso D, Smastuen MC, et al
     Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial.
     Ann Intern Med. 2021 Nov 30. doi: 10.7326/M21-1962.
     PubMed     Abstract available
     
     
     
133. GANDHI GY
     In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide.
     Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
     PubMed     Abstract available
     
     
     October 2021
134. OLSON DE
     In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control.
     Ann Intern Med. 2021 Oct 5. doi: 10.7326/ACPJ202110190.
     PubMed     Abstract available
     
     
     
135. JENKINS I
     Medical Violence.
     Ann Intern Med. 2021;174:1472-1473.
     PubMed    
     
     
     September 2021
136. PATORNO E, Htoo PT, Glynn RJ, Schneeweiss S, et al
     Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
     Ann Intern Med. 2021 Sep 28. doi: 10.7326/M21-0893.
     PubMed     Abstract available
     
     
     
137. BOGGILD MK, Cheung AM
     Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM.
     Ann Intern Med. 2021;174:JC106.
     PubMed     Abstract available
     
     
     June 2021
138. GANDRA S, Ram S, Levitz SM
     The "Black Fungus" in India: The Emerging Syndemic of COVID-19-Associated Mucormycosis.
     Ann Intern Med. 2021 Jun 8. doi: 10.7326/M21-2354.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.